Ryan Oliver

Ryan Oliver is a seasoned professional in the field of genetic medicines and oligonucleotide chemistry, currently serving as Principal Scientist II and Associate Director at AbbVie since March 2025. Prior to this role, Ryan was the Director of Oligonucleotide Chemistry at Aliada Therapeutics from March 2024 to March 2025, where management of internal oligonucleotide discovery programs and lab buildout occurred following the company's acquisition by AbbVie in December 2024. Ryan's experience includes serving as Associate Director of Discovery Biology at Sarepta Therapeutics from January 2019 to March 2024, overseeing a team of twelve scientists to drive RNA discovery programs. Earlier career milestones include a significant role as a Ph.D. Candidate at The Johns Hopkins University, where the discovery and characterization of the first monobactam gene cluster took place, and as a Researcher during an NSF REU Research Fellowship at Furman University. Ryan holds a Ph.D. and an MA in Chemistry from The Johns Hopkins University, as well as a research fellowship in Medicinal Chemistry from Furman University.